Posted On: 10/15/2014 9:50:08 PM
Post# of 30039
”With this grant, our team of investigators will accelerate the work to gain a better insight into the disease mechanism, which should pave the way for the development of specific treatments,” says Wen.
http://investorshangout.com/post/view?id=2144111
“We are quite excited about the possibilities for MANF,” said Rong Wen, M.D., Ph.D., professor of ophthalmology and the Bascom Palmer scientist whose research has demonstrated the efficacy of MANF in experimental models of retinal degeneration. “The next step will be to develop the proper method of delivering it to the back of the eye.”
In a deal that may lead to the first viable treatment for retinal diseases, Amarantus Bioscience Holdings, Inc., a biotechnology company, has exercised its exclusive right to license intellectual property related to a protein product developed by a researcher at the Miller School of Medicine’s Bascom Palmer Eye Institute.
http://med.miami.edu/news/bascom-palmer-licen...ch-company
"With interim toxicology data now in hand, and with multiple data sets forthcoming in the third and fourth quarter for the MANF ophthalmology program focused initially on Retinitis pigmentosa, we believe now is the ideal time to exercise our option and move forward under the auspices of a full license agreement,"
http://ir.amarantus.com/company-news/detail/1...-disorders
http://investorshangout.com/post/view?id=2144111
“We are quite excited about the possibilities for MANF,” said Rong Wen, M.D., Ph.D., professor of ophthalmology and the Bascom Palmer scientist whose research has demonstrated the efficacy of MANF in experimental models of retinal degeneration. “The next step will be to develop the proper method of delivering it to the back of the eye.”
In a deal that may lead to the first viable treatment for retinal diseases, Amarantus Bioscience Holdings, Inc., a biotechnology company, has exercised its exclusive right to license intellectual property related to a protein product developed by a researcher at the Miller School of Medicine’s Bascom Palmer Eye Institute.
http://med.miami.edu/news/bascom-palmer-licen...ch-company
"With interim toxicology data now in hand, and with multiple data sets forthcoming in the third and fourth quarter for the MANF ophthalmology program focused initially on Retinitis pigmentosa, we believe now is the ideal time to exercise our option and move forward under the auspices of a full license agreement,"
http://ir.amarantus.com/company-news/detail/1...-disorders
(0)
(0)Scroll down for more posts ▼
